Compare IREN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IREN | MIRM |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.2B |
| IPO Year | 2021 | 2019 |
| Metric | IREN | MIRM |
|---|---|---|
| Price | $14.41 | $95.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 12 |
| Target Price | $56.69 | ★ $157.71 |
| AVG Volume (30 Days) | ★ 54.9M | 514.2K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $707,007,000.00 | $19,138,000.00 |
| Revenue This Year | $237.43 | $37.65 |
| Revenue Next Year | $199.66 | $21.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 41.11 | N/A |
| 52 Week Low | $14.98 | $63.23 |
| 52 Week High | $70.71 | $130.00 |
| Indicator | IREN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 26.73 | 60.65 |
| Support Level | N/A | $87.38 |
| Resistance Level | $44.21 | $98.34 |
| Average True Range (ATR) | 2.13 | 4.13 |
| MACD | -0.17 | 0.32 |
| Stochastic Oscillator | 2.29 | 75.22 |
IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operations. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.